Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World April 15, 2003 Michael Greeley	Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive?
Bio-IT World July 15, 2003 Michael Greeley	Finally, the Bottom Has pharma bought all the solutions it needs? The flood of genomic data indicates no.
Bio-IT World May 9, 2003 Michael Greeley	Mechanistic Models Investors are backing predictive modeling software that could speed drug development.
Bio-IT World October 10, 2003	Funds Up Venture financing numbers are in for Q2, and the news is not all bad.
Pharmaceutical Executive October 1, 2011	Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare.
Bio-IT World Dec 2005/Jan 2006 Michael A. Greeley	Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s.
Bio-IT World January 13, 2003 Michael Greeley	What Do We Do Now? Like it or not, the supply of capital is an important ingredient in the continued development of the bio-IT industry. Appreciating and understanding the forces currently at work in the VC marketplace can only help in raising capital.
Bio-IT World December 15, 2003 Michael Greeley	Tiny Devices, Big Opportunities Parallel advances in drug formulation and microprocessing and other manufacturing technologies are creating new products and services as these industries start to intersect.
Bio-IT World March 17, 2004	Signs of Spring Colin Hill, CEO of Gene Network Sciences, a predictive systems biology company, says the worst is behind the bio-IT industry. "The hype has dissipated, and companies are focused on delivering the results," he says. Hill's strategy includes developing additional products, which should generate near-term revenue.
Bio-IT World October 14, 2004 Michael Greeley	Go East Business is great in China, and the government is strongly encouraging the local biotech industry.
Bio-IT World June 15, 2003 Michael Greeley	Six-Million-Dollar Questions As the healthcare marketplace homogenizes, product and service prospects will improve.
Bio-IT World March 10, 2003 Michael Greeley	Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand?
Bio-IT World September 2005 Michael A. Greeley	Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets.
CRM November 2009 Lauren McKay	Pharmaceuticals -- CRM Undergoes an Experimental New Treatment An older CRM vertical gets a new dose of on-demand technology.
Bio-IT World August 13, 2003 Michael Greeley	Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous.
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay	Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole.
Pharmaceutical Executive June 1, 2007 Michael Goodman	A Very Specialty Moment Big Pharma is on a shopping spree for biologics and other specialty products. It has the money to buy them. But does it have the mojo to develop and market them successfully - or will the mid-size biopharmas make their big move?
Pharmaceutical Executive June 1, 2005 Boschwitz et al.	Track Patients, Not Prescriptions Why pharma companies reject anonymous patient-level data, and why they can't do without it for long.
Bio-IT World November 14, 2003 Michael Greeley	Show You the Money Venture capitalists need to balance two, at times conflicting, parameters when considering compensation for the executives at biotech companies in their portfolios: cash and long-term equity incentives.
HBS Working Knowledge June 29, 2015 Dina Gerdeman	Consumer-centered Health Care Depends on Accessible Medical Records John Quelch discusses approaches to integrate patient data so that medical professionals and patients can make better decisions.
Pharmaceutical Executive June 1, 2012 Amy Smith	Marketing: Medical Devices vs. Pharma Understanding the differences between drug and device marketing can make or break the brand's promotional activities.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Pharmaceutical Executive October 1, 2008 Patrick Clinton	Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
Bio-IT World March 2007 Michael A. Greeley	Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities.
Pharmaceutical Executive September 1, 2012 Al Topin	Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty.
Pharmaceutical Executive July 1, 2012 William Looney	The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.
Bio-IT World June 17, 2004 Michael A. Greeley	A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools.
Bio-IT World June 2006 Michael A. Greeley	Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process.
Pharmaceutical Executive January 1, 2012 Elys Roberts & Sarah Phillips	The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Pharmaceutical Executive March 1, 2012 Ringler & Comer	The (Life) Science of Digital Connections Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
Pharmaceutical Executive May 1, 2006 Stephen Wray	Alternative Media: Interactive=Integration Interactive technology allows marketers to keep up with the demands of both physicians and consumers.
Pharmaceutical Executive April 1, 2006 David Duplay	Marketing to Professionals: A Sample Plan Sure, pharmaceutical e-sampling can save money. But there are plenty of other reasons to use it.
Pharmaceutical Executive May 1, 2012	Super-Size Me Finding opportunities in the information explosion: big data, big challenges and big rewards.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
Pharmaceutical Executive October 1, 2008	Getting Personal(ized) Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.
Bio-IT World January 12, 2004 Michael A. Greeley	What You See Is What You Get Better image analysis, better business models. The transition from analog to digital will allow systems biology to reach its full potential.
Pharmaceutical Executive February 1, 2014 Anbil et al.	Managed Markets: Positioning Your Product For Success with Pull Through Strategies A patient-centric approach to drug development delivers the benefits that actually create value
Pharmaceutical Executive June 1, 2006 Nancy Dreyer	Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials.
Pharmaceutical Executive December 1, 2011 William Looney	The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda.
CIO September 27, 2013	How IT Can Produce Better Patient Care For Dr. Bob Laskowski, president and CEO of Christiana Care Health System, technology means empowering physicians and patients.
Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
Pharmaceutical Executive September 1, 2010 Marylyn Donahue	With a Little Help from their Peers Physician meetings drive prescribing behavior, but what are the marketing meetings doctors prefer, and who are they listening to?
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Bio-IT World April 2006 Michael A. Greeley	The Good, The Bad, and The Ugly VCs will not support a sector where consistent compelling exits are not evident. Unfortunately, the bio-IT field still suffers from this.
Pharmaceutical Executive February 1, 2012 Sarah Krug	Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
Pharmaceutical Executive April 10, 2014	Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive June 1, 2013 Clark Herman	Adherence's New Players: Fresh Support from the Sidelines New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.